Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer

Published:2008-12 Issue:12 Volume:19 Page:2033-2038
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Milano G.,Etienne-Grimaldi M.-C.,Dahan L.,Francoual M.,Spano J.-P.,Benchimol D.,Chazal M.,Letoublon C.,André T.,Gilly F.-N.,Delpero J.-R.,Formento J.-L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/12/2033/398760/mdn416.pdf

Reference34 articles.

1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

2. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor;Saltz;J Clin Oncol,2004

3. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study;Moroni;Lancet Oncol,2005

4. Hyperactive Ras in developmental disorders and cancer;Schubbert;Nat Rev Cancer,2007

5. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer;Lièvre;Cancer Res,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate cancer expressing membrane-bound TGF-α induces bone formation mediated by the autocrine effect of prostaglandin E2 in osteoblasts;Biochemical and Biophysical Research Communications;2023-02

2. CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?;ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo);2021

3. Anti-EGFR therapies in nasopharyngeal carcinoma;Biomedicine & Pharmacotherapy;2020-11

4. NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children;Experimental Hematology & Oncology;2019-05-09

5. A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer;Clinical Colorectal Cancer;2016-09